Assessment of myocardial sympathetic innervation with 18F-FDOPA-PET/CT in patients with autonomic dysfunction: feasibility study in IPD patients

Goyal, Harish; Sharma, Anshul; Patel, Chetan; Deepak, Kishore Kumar; Tripathi, Madhavi; Gupta, Priyanka; Kumar, Rajeev; Bal, Chandra Shekhar; Goyal, Vinay

doi:10.1007/s12350-020-02474-w

Cited by 6 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one group of patients with clinically diagnosed heart failure, regional and global deficits in [ 18 F]FDOPA uptake, defined by decreasing MMR, relative to healthy controls [79]. Additionally, [ 18 F]FDOPA documents cardiac sympathetic dysfunction in patients with advanced idiopathic Parkinson's disease [80].…”

Section: Innervationmentioning

confidence: 99%

PET Tracers for Imaging Cardiac Function in Cardio-oncology

Kelly

Babich

2022

Curr Cardiol Rep

View full text Add to dashboard Cite

Purpose of Review Successful treatment of cancer can be hampered by the attendant risk of cardiotoxicity, manifesting as cardiomyopathy, left ventricle systolic dysfunction and, in some cases, heart failure. This risk can be mitigated if the injury to the heart is detected before the onset to irreversible cardiac impairment. The gold standard for cardiac imaging in cardio-oncology is echocardiography. Despite improvements in the application of this modality, it is not typically sensitive to sub-clinical or early-stage dysfunction. We identify in this review some emerging tracers for detecting incipient cardiotoxicity by positron emission tomography (PET). Recent Findings Vectors labeled with positron-emitting radionuclides (e.g., carbon-11, fluorine-18, gallium-68) are now available to study cardiac function, metabolism, and tissue repair in preclinical models. Many of these probes are highly sensitive to early damage, thereby potentially addressing the limitations of current imaging approaches, and show promise in preliminary clinical evaluations. Summary The overlapping pathophysiology between cardiotoxicity and heart failure significantly expands the number of imaging tools available to cardio-oncology. This is highlighted by the emergence of radiolabeled probes targeting fibroblast activation protein (FAP) for sensitive detection of dysregulated healing process that underpins adverse cardiac remodeling. The growth of PET scanner technology also creates an opportunity for a renaissance in metabolic imaging in cardio-oncology research.

show abstract

Section: Innervationmentioning

confidence: 99%